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ABSTRACT
Background    Left subclavian artery (LSA) emboliza-
tion is occasionally required to prevent type II endoleak 
in the thoracic endovascular aortic repair (TEVAR) 
procedure. This is a retrospective study comparing com-
pressed Amplatzer Vascular Plug II embolization (CAE) 
and conventional coil embolization (CCE) in preventing 
retrograde flow into the aneurysmal sac through the 
LSA after TEVAR.
Methods    We retrospectively reviewed the records of 
patients who underwent CAE or CCE of the LSA during 
TEVAR from June 2013 to March 2016 in our hospital. 
The efficacy, safety and cost of each method were com-
pared between two groups.
Results    Thirty patients underwent LSA embolization 
during TEVAR. Six CCEs in 6 patients were performed 
from June 2013 to November 2013, while twenty-four 
CAEs in 24 patients were performed from December 
2013 to March 2016. Technical success was achieved 
in all patients in both groups. No embolization-related 
complications or type II endoleaks from LSA were 
recorded during the follow-up period in all patients. In 
both groups, all embolic materials were detected in the 
proximal portion of the LSA from the LSA orifice to the 
vertebral artery origin and no vertebral artery occlusions 
were detected. The mean compression ratio of AVP II 
was 58 ± 5.9% of predicted length of standard proce-
dure. In the CAE group, one AVP II was sufficient to 
achieve complete LSA occlusion in all patients. On the 
other hand, multiple coils (10.2 ± 2.7) were used in the 
CCE group (P < .01), resulting in a significantly lower 
cost incurred in the CAE group (CAE: 129,000 JPY vs. 
CCE: 639,600 ± 140,060 JPY; P < .01). 
Conclusion    The CAE is a useful and cost-effective 
procedure for TEVAR-related LSA embolization.
Key words    endovascular procedures; aortic aneurysm; 
subclavian artery; embolization
In order to establish the requisite landing zone for thoracic 
endovascular aortic repair (TEVAR), it is often necessary 
to cover the orifice of the left subclavian artery (LSA) 
with an endovascular graft. This procedure has been 
performed in up to 68.0% of repairs.1–4 In such situations, 
retrograde flow through the LSA may cause a type II en-
doleak, aneurysmal sac expansion or rupture.1, 5–9 As such, 
LSA occlusion is a procedure that is widely established 
to be necessary in TEVAR.
 Embolization of the proximal portion of the LSA 
from the LSA orifice to the vertebral artery origin 
has been traditionally performed by conventional coil 
embolization (CCE). CCE, while often successful, can 
occasionally be problematic because of coil misplace-
ment and the need for multiple coils (Fig. 1).9 In the last 
decade, Amplatzer Vascular Plug II (AVP II) (St. Jude 
medical, St. Paul, MN) has been commercially available 
in Japan. AVP II has three multi-layered nitinol mesh 
lobes for rapid embolization of the vessel and has since 
been used for embolization of the internal iliac artery 
during endovascular aortic repair for abdominal aortic 
aneurysms.10 The effectiveness of AVP II embolization 
for the LSA in selected cases has also been reported 
in the literature.5, 11, 12 However, AVP II application for 
the LSA is technically difficult because the proximal 
portion of the LSA from the LSA orifice to the vertebral 
artery origin is not long enough for the AVP II place-
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Table 1. Demographics, cardiovascular risk factors, and perioperative risk assessment in 30 left subclavian ar-
tery embolizations during thoracic endovascular aortic repair 
CAE group CCE group
(n = 24) (n = 6) P value
Age 76 ± 11 79 ± 6 0.80 
Male gender 22 91.67% 5 83.33% 0.50 
BMI 22.0 ± 3.2 21.1 ± 3.2 0.59 
Hypertension 21 87.50% 5 83.33% 1.00 
Hyperlipidemia 11 45.83% 3 50.00% 1.00 
Coronary artery disease 2 8.33% 1 16.67% 0.50 
Prior MI 1 4.17% 0 0.00% 1.00 
CHF 3 12.50% 0 0.00% 1.00 
Atrial fibrillation 1 4.17% 1 16.67% 1.00 
Tobacco history 15 62.50% 5 83.33% 0.63 
COPD 6 25.00% 1 16.67% 1.00
Diabetes mellitus 2 8.33% 1 16.67% 0.50 
CKD (eGFR < 45) 10 41.67% 0 0.00% 0.07 
eGFR (mL/min/1.73m3) 51.1 ± 25.9 83.2 ± 23.0 0.03
Cerebrovascular disease 4 16.67% 0 0.00% 0.56 
Peripheral artery disease 2 8.33% 0 0.00% 1.00 
Cancer 7 29.17% 2 33.33% 1.00 
Pathology
Degenerative aortic aneurysm 21 87.50% 6 100.00% 1.00 
Aortic dissection 3 12.50% 0 0.00% 1.00 
Emergency 3 12.50% 0 0.00% 1.00 
BMI, body mass index; CAE, compressed Amplatzer Vascular Plug II embolization; CCE, conventional coil embolization; CHF, conges-
tive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration 
rate; MI, myocardial infarction.
Fig. 1. The schema of appropriate AVP II placement by CAE 
and potential inappropriate coil placement by CCE method. AVP 
II, Amplatzer Vascular Plug II; CAE, compressed Amplatzer 
Vascular Plug II embolization; CCE, conventional coil emboliza-
tion
Fig. 2. The picture of placed AVP II by conventional and by com-
pressing method in tube model. AVP II, Amplatzer Vascular Plug 
II.
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ment. Consequently, we have developed an embolization 
technique using the compression method of all three 
lobes of AVP II (CAE) and confirmed the efficacy of 
this technique in animal experiments (unpublished data). 
Our aim was to evaluate safety and efficacy of CAE 
method during TEVAR.
MATERIALS AND METHODS
This present study was approved by the institutional 
review board of the authors’ institution (1704A012). We 
retrospectively reviewed the records of 30 patients from 
June 2013 to March 2016. Patient demographics and 
pathologies are summarized in Table 1.
Embolization procedures
In the CAE group, 5 or 6-French guiding sheath in-
troducer (Destination; Terumo Medical Corporation, 
Tokyo, Japan) was inserted by the transaxillary approach 
with surgical cut-down or percutaneous transbrachial 
approach. The inner diameter of the LSA was measured 
by contrast enhanced computed tomography (CT) in 
advance. The AVP II that was approximately 30–50% 
larger than the maximum diameter of the LSA was 
selected. When the AVP II reached the proximal portion 
of the LSA, the fi rst lobe of the AVP II was deployed. 
Then, the introducer sheath was used to compress the 
fi rst lobe. The second and third lobes were subsequently 
compressed in the same manner (Fig. 2). In the CCE 
group, coaxial intubation of the LSA was performed 
with a microcatheter (Progreat β3; Terumo Medical 
Corporation, Tokyo, Japan) using a percutaneous trans-
brachial approach. LSA occlusion was achieved with de-
tachable microcoils (Interlock; Boston Scientifi c, Natic, 
MA) with the choice of the appropriate coil size based 
on the diameter of the LSA. Finally, complete LSA oc-
clusion was confi rmed by retrograde digital subtraction 
angiography. The stent-graft deployment was done prior 
or subsequent to the LSA embolization. 
Evaluation of treatment and patient follow-up
Technical success (defined as successful compression 
and placement of AVP II without sealing the LSA 
orifi ce) and complication rate of LSA embolization and 
the TEVAR procedure were evaluated. The amount 
of embolic material in the LSA by both methods was 
compared. To evaluate the device length of the AVP II 
by compression, we calculated the compression ratio by 
comparing the compressed AVP II length in the LSA to 
uncompressed AVP II length in the ex-vivo tube model 
(Fig. 3). For prediction of the length of deployed AVP 
II using the conventional technique, the length of un-
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Fig. 4. Images from an 82-year-old man with type B dissection 
and 6.0-cm proximal descending thoracic aneurysm treated with 
a stent-graft (GORE CTAG; W.L. Gore & Associates, Flagstaff, 
AZ) across the origin of the subclavian artery. A: Sagittal 
multi-planar reconstruction image of thoracic CT angiogram 
before stent-grafting demonstrates the aneurysm. The proximal 
portion of LSA was 10-mm in diameter and AVP II 14-mm in 
diameter was selected for embolization. The landing zone for AVP 
II embolization, from the proximal portion of LSA to the bifurca-
tion of vertebral artery, was 42-mm long that was slightly shorter 
than conventional AVP II deployment in tube model 46-mm. B: 
Angiogram after CAE and stent-grafting. C: Sagittal multi-planar 
reconstruction image of thoracic CT angiogram after TEVAR 
demonstrates the absence of endoleak and that the bifurcation of 
vertebral artery was maintained. AVP II, Amplatzer Vascular Plug 
II; CAE, compressed Amplatzer Vascular Plug II embolization; 
CT, computed tomography; LSA, left subclavian artery; TEVAR, 
thoracic endovascular aortic repair.
Fig. 3. The schema of conventional AVP II embolization and com-
pressed AVP II embolization. The compression ratio of the short-
ening length of AVP II to the length of AVP II with conventional 
deployment in tube model was calculated. AVP II, Amplatzer 
Vascular Plug II.
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in the ex-vivo tube model. When an AVP II of device 
size of 16mm was deployed using the uncompressed 
conventional technique in the ex-vivo tube model whose 
inner diameter were 11 and 12 mm, while the length of 
deployed AVP II were 52 and 49 mm, respectively. In 
cases of AVP II 14 mm and tube models of 9, 10, and 
11 mm, the length of deployed AVP II were 50, 46, and 
42 mm, respectively. In AVP II 12 mm and tube models 
9, 8 mm, the lengths of deployed AVP II were 36, 42 
mm, respectively. In AVP II 10 mm, tube model 8 mm, 
the length of deployed AVP II was 29 mm (unpublished 
data).
 The costs of devices used for embolization, accord-
ing to redemption prices determined in the health insur-
ance programs in Japan, were also compared between 
the two groups.
 The dynamic contrast enhanced CT was performed 
at 1 week, 6 and 12 months after the TEVAR procedure. 
Clinical success was defined as the absence of type 
II endoleak from the LSA on follow-up CT. Patient 
demographics, treatment modalities and outcomes were 
compared (Fig. 4).
 A comparison of continuous variables was made 
using the Mann–Whitney U test for independent vari-
ables, while categorical variables were compared using 
Fisher’s exact test with the IBM SPSS Statistics version 
24. Differences were considered significant if the two-
tailed P value was < .05.
RESULTS
Procedures and perioperative period
The CCE was performed in 6 patients, while the CAE 
was performed in 24 patients. The patients in the CAE 
group, aged 31–90 years (mean 76.2), consisted of 22 
males (91.7%) and 2 females. The patients in the CCE 
group, aged 69–88 (mean 78.7), consisted of 5 males and 
1 female. Both groups had similar demographics and 
cardiovascular risk factors, with the exception of a great-
er rate of chronic kidney disease in the CAE group (CAE: 
42%, CCE: 0%, P = .05). Selective revascularization was 
performed in 3 patients (50.0%) in the CCE group and 
20 patients in the CAE group (83.3%).  
 Technical success of LSA embolization was 
achieved at 100 % in both groups (Table 2). In the 
CAE group, the AVP II of the device size 10, 12, 14 
and 16mm were used for embolization of the LSA with 
an inner diameter of 8–12 (mean 10.0 ± 0.9) mm. The 
length of compressed AVP II was 15–24 (mean 19.0 ± 
3.6) mm. The length of the proximal portion of the LSA 
from the LSA orifice to the vertebral artery origin was 
24–62 (mean 41.7 ± 8.9) mm in the CAE group and the 
length of uncompressed AVP II was 29–52 (mean 45.9 
± 4.9) in the tube model. In seventeen patients of the 
CAE group (70.8%), the length of uncompressed AVP 
II in the tube model was equal to or larger than that of 
the proximal portion of the LSA from the LSA orifice to 
the vertebral artery origin in the CAE group. The mean 
compression ratio of AVP II was 58.6 ± 5.9 %. 
Table 2. Left subclavian artery embolization details
CAE group CCE group
(n = 24) (n = 6) P value
Technical success 24 (100%) 6 (100%) 1.00
Diameter of LSA proximal 
portion (mm) 10.0 ± 1.1 9.5 ± 1.5 0.47
Landing zone in LSA (mm) 41.7 ± 8.9 42.7 ± 6.3 0.98 
The length of embolization 
material (mm) 19.0 ± 3.6 33.2 ± 5.8 **< 0.01
The length of the uncom-
pressed AVP II with standard 
procedure in tube model (mm)
45.9 ± 4.9
No. of embolization materials 1 10.2 ± 2.7 **< 0.01
Cost of embolization materi-
als (JPY) 129,000
639,600
± 140,060 **< 0.01
AVP II, Amplatzer Vascular Plug II; CAE, compressed Amplatzer 
Vascular Plug II embolization; CCE, conventional coil emboliza-
tion; JPY, Japanese yen; LSA, Left subclavian artery.
 In the CAE group, emergency TEVAR was applied 
for ruptured thoracic aortic aneurysm. No major compli-
cation such as a stroke or shower embolism was noticed 
in all but one patient. One patient died from a re-rupture 
of an aneurysmal sac due to type 1b endoleak seven days 
after the TEVAR. Although a larger-sized introducer 
was used in CAE, there was no significant difference in 
any access route-related complications in both groups.  
 The number of embolization material in the CAE 
group and CCE group were one and 10.2 ± 2.7, respec-
tively (P < .01). The costs incurred from embolization 
material were lower in the CAE group (CAE: 129,000 
JPY, CCE: 639,600 ± 140,060 JPY, P < .01).
Follow-up period
The mean follow-up period was 381 days (range, 7–768 
days) in the CAE group, and 942 days (range, 714–1116 
days) in the CCE group. Although type II endoleak was 
detected in five CAEs and three CCEs, no LSA-related 
endoleak was observed. Migration of any embolic 
material was not found. No ischemic symptoms of the 
left arm due to the LSA embolization were recorded 
throughout the follow-up period. Aneurysmal sac 
enlargement of more than 5 mm in diameter was not 
observed in any case within the follow-up period.
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DISCUSSION
TEVAR has become increasingly popular in the treat-
ment of aneurysms and type B aortic dissections.13–17 
When the proximal end of the aneurysmal sac or entry 
tear is close to the orifice of LSA, it is often necessary 
to cover the LSA orifice to establish this required 
landing zone for stent-grafting. Patency of the proximal 
portion of the LSA may cause a type II endoleak. Type 
II endoleaks may resolve spontaneously, but persistent 
pressurization of the aneurysmal sac places the patient at 
risk of sac rupture.5 Consequently, the presence of a type 
II endoleak, particularly in the setting of aneurysm sac 
enlargement, is an indicator of a poor clinical outcome 
and requires repair.9 LSA occlusion, with or without sur-
gical arch debranching, is needed to prevent type II en-
doleak. Conventional occlusion methods of the proximal 
portion of the LSA to deal with type II endoleak include 
surgical ligation or catheter-directed embolization with 
metal coils or glue.3 
 AVP II prosthesis, which is an excellent vessel occlu-
sion device for medium to large vessels with high flow, 
consists of nitinol mesh with varying numbers of wires 
(144 to 360) with different designs (one to three layers of 
wires). It has three lobes of equal diameter without the 
presence of tissue inside. Meyer et al. reported AVP II 
to be a safe and easy-to-use instrument demonstrating 
rapid permanent occlusion of the left-subclavian back 
flow type II endoleak.18 However, AVP II embolization 
requires a specific length of arterial segment because 
three lobes of AVP II are deployed by their extension 
in the arterial lumen. In addition, the length of the 
proximal portion of the LSA from the LSA orifice to the 
vertebral artery origin of the LSA is often too short for 
AVP II placement with the uncompressed conventional 
technique. In our study, the length of the proximal 
potion of the LSA was equal to or shorter than AVP II 
length with the conventional procedure in the tube mod-
el in seventeen patients of the CAE group (70.8%). Even 
in such situations, we could successfully embolize the 
proximal portion of the LSA using compressed AVP II.
 Concerning the application of compressed AVP II 
for the embolization of LSA, there are several risks to 
consider. The lobe deformity of AVP II by compression 
might cause insufficient occlusion. In addition, the 
compression may cause distal embolization from athero-
thrombotic debris because of abrasion of the surface of 
the artery from the mesh lobe during the procedure. To 
resolve these risks, we have performed animal experi-
ments using swine (unpublished data). From this study, 
we have histologically confirmed the safety of compres-
sion of AVP II. In all CAE patients of our series, AVP 
IIs were adapted to LSA embolization by compression. 
CAE could provide effective LSA embolization without 
any complications on TEVAR combined with or without 
debranching bypass. Although, a larger-sized introducer 
sheath is necessary to deliver the AVP II, no significant 
differences in complication rate were observed between 
CAE and CCE. 
 The cost of embolization devices such as Amplatzer 
vascular plugs and standard coils have been reviewed by 
several investigators. American investigators found that 
the Amplatzer vascular plug was 69% less expensive 
based on the cost of the coils or plug alone in translumi-
nal hypogastric artery occlusion during abdominal endo-
vascular aortic repair.17 In the series by Vandy et al.,17 7.53 
coils were utilized compared with 1.35 plugs. European 
investigators found that the Amplatzer plug was 71% 
less expensive based on the cost of the devices alone for 
occlusion of the internal iliac artery.19 In our series, 10.2 
coils were placed compared with only one plug. As such, 
the CAE cost 80% less than the CCE, corroborating 
findings from those reports. As such, CAE can reduce 
the cost of embolization devices.
 Being a retrospective study, the present study has 
several limitations including lack of randomization. In 
addition, the sample size is relatively small, especially 
in the CCE group. First, although no major stroke was 
seen in this study, we did not evaluate the incidence of 
subclinical cerebral infarction during the embolization 
procedure. Further examination is required with regard 
to the incidence of micro cerebral embolism. Second, the 
procedure time of CCE or CAE could not be compared 
because it was not recorded, while the whole procedure 
time of TEVAR was recorded. Third, the pressure on the 
vessel wall by compressing method was not evaluated.
 In the present study, we retrospectively reviewed 
success rate and safety of CAE and compared with 
CCE. We designed the CAE for prevention of type 
II endoleaks associated with TEVAR for distal arch 
pathology. CAE was found to be safe and effective for 
LSA proximal embolization. CAE can reduce the cost 
of embolization devices and as such, CAE could be a 
candidate to supplant CCE.
The authors declare no conflict of interest.
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